Not found

Yulin Li, MD, PhD

Assistant Professor of Immunotherapy in Oncology, Academic Institute
Assistant Member, Research Institute
Houston Methodist
Weill Cornell Medical College


Biography

Dr. Li finished his medical school at Beijing Medical University and his graduate school at Penn State. He had his postdoctoral training at Stanford University before joining the Research Institute in late 2017.

Description of Research

Dr. Li's research interests includes 1) Roles of oncogenes in tumorigenesis, and 2) Rational combination therapy.  Dr. Li's lab utilizes both experimental and computational approaches to study cancer and rare diseases.

Areas Of Expertise

Proteomics in oncology Combination therapy Differentiation
Publications

XPO1-dependent nuclear export as a target for cancer therapy
Azizian, NG, Azizian, NG, Li, Y & Li, Y 2020, , Journal of Hematology and Oncology, vol. 13, no. 1, 61. https://doi.org/10.1186/s13045-020-00903-4

Simultaneous targeting of XPO1 and BCL2 as an effective treatment strategy for double-hit lymphoma
Liu, Y, Azizian, NG, Dou, Y, Pham, LV & Li, Y 2019, , Journal of Hematology and Oncology, vol. 12, no. 1. https://doi.org/10.1186/s13045-019-0803-9

Mebendazole for Differentiation Therapy of Acute Myeloid Leukemia Identified by a Lineage Maturation Index
Li, Y, Thomas, D, Deutzmann, A, Majeti, R, Felsher, DW & Dill, DL 2019, , Scientific Reports, vol. 9, no. 1, pp. 16775. https://doi.org/10.1038/s41598-019-53290-3

Rational Targeted Therapeutics for Double-Hit Lymphoma
Li, Y 2019, International Journal of Hematologic Oncology.

BIM-mediated apoptosis and oncogene addiction
Li, Y, Deutzmann, A & Felsher, DW 2016, Aging, vol. 8, no. 9, pp. 1834-1835. https://doi.org/10.18632/aging.101072

BIM mediates oncogene inactivation-induced apoptosis in multiple transgenic mouse models of acute lymphoblastic leukemia
Li, Y, Deutzmann, A, Choi, PS, Fan, AC & Felsher, DW 2016, , Oncotarget, vol. 7, no. 19, pp. 26926-26934. https://doi.org/10.18632/oncotarget.8731

MYC regulates the antitumor immune response through CD47 and PD-L1
Casey, SC, Tong, L, Li, Y, Do, R, Walz, S, Fitzgerald, KN, Gouw, AM, Baylot, V, Gütgemann, I, Eilers, M & Felsher, DW 2016, , Science, vol. 352, no. 6282, pp. 227-231. https://doi.org/10.1126/science.aac9935

MYC oncogene overexpression drives renal cell carcinoma in a mouse model through glutamine metabolism
Shroff, EH, Eberlin, LS, Dang, VM, Gouw, AM, Gabay, M, Adam, SJ, Bellovin, DI, Trand, PT, Philbrick, WM, Garcia-Ocana, A, Casey, SC, Li, Y, Dang, CV, Zare, RN & Felsher, DW 2015, , Proceedings of the National Academy of Sciences of the United States of America, vol. 112, no. 21, pp. 6539-6544. https://doi.org/10.1073/pnas.1507228112

miR-17–92 explains MYC oncogene addiction
Li, Y, Casey, SC, Choi, PS & Felsher, DW 2014, , Molecular and Cellular Oncology, vol. 1, no. 4, e970092. https://doi.org/10.4161/23723548.2014.970092

Activation of cre recombinase alone can induce complete tumor regression
Li, Y, Choi, PS, Casey, SC & Felsher, DW 2014, , PLoS ONE, vol. 9, no. 9, e0107589. https://doi.org/10.1371/journal.pone.0107589

Addiction to multiple oncogenes can be exploited to prevent the emergence of therapeutic resistance
Choi, PS, Li, Y & Felsher, DW 2014, , Proceedings of the National Academy of Sciences of the United States of America, vol. 111, no. 32, pp. E3316-E3324. https://doi.org/10.1073/pnas.1406123111

MYC through miR-17-92 suppresses specific target genes to maintain survival, autonomous proliferation, and a Neoplastic state
Li, Y, Choi, PS, Casey, SC, Dill, DL & Felsher, DW 2014, , Cancer Cell, vol. 26, no. 2, pp. 262-272. https://doi.org/10.1016/j.ccr.2014.06.014

Oncogene withdrawal engages the immune system to induce sustained cancer regression
Casey, SC, Li, Y, Fan, AC & Felsher, DW 2014, , Journal for immunotherapy of cancer, vol. 2, no. 1, 24. https://doi.org/10.1186/2051-1426-2-24

Inactivation of MYC reverses tumorigenesis
Li, Y, Casey, SC & Felsher, DW 2014, , Journal of Internal Medicine, vol. 276, no. 1, pp. 52-60. https://doi.org/10.1111/joim.12237

An essential role for the immune system in the mechanism of tumor regression following targeted oncogene inactivation
Casey, SC, Li, Y & Felsher, DW 2014, , Immunologic Research, vol. 58, no. 2-3, pp. 282-291. https://doi.org/10.1007/s12026-014-8503-6

Oncogene addiction: Resetting the safety switch?
Li, Y, Choi, PS & Felsher, DW 2014, , Oncotarget, vol. 5, no. 18, pp. 7986-7987. https://doi.org/10.18632/oncotarget.2474

MYC activation is a hallmark of cancer initiation and maintenance
Gabay, M, Li, Y & Felsher, DW 2014, , Cold Spring Harbor Perspectives in Medicine, vol. 4, no. 6. https://doi.org/10.1101/cshperspect.a014241

PERK eIF2 alpha kinase is required to regulate the viability of the exocrine pancreas in mice
Iida, K, Li, Y, McGrath, BC, Frank, A & Cavener, DR 2007, , BMC Cell Biology, vol. 8, 38. https://doi.org/10.1186/1471-2121-8-38

PERK EIF2AK3 control of pancreatic ß cell differentiation and proliferation is required for postnatal glucose homeostasis
Zhang, W, Feng, D, Li, Y, Iida, K, McGrath, B & Cavener, DR 2006, , Cell Metabolism, vol. 4, no. 6, pp. 491-497. https://doi.org/10.1016/j.cmet.2006.11.002

Proinsulin disulfide maturation and misfolding in the endoplasmic reticulum
Liu, M, Li, Y, Cavener, D & Arvan, P 2005, , Journal of Biological Chemistry, vol. 280, no. 14, pp. 13209-13212. https://doi.org/10.1074/jbc.C400475200